Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
04 January 2012
Nancy Faigen
Please Login to read the full article.
04 January 2012
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Major disappointment for Targacept and AstraZeneca in Phase III depression trial
- Lundbeck CEO outlines commercial strategy for alcohol-dependency and depression candidates
- Payers addicted to addiction, says Pops, as Alkermes shows sustained opiate abstinence
- AstraZeneca to take $381.5 million charge after two major trial failures
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
